)
Visual
test
Calliditas Therapeutics
Calliditas Therapeutics (CALTX) investor relations material
Calliditas Therapeutics Q2 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2024 earnings summary13 Aug, 2024
Executive summary
Achieved record Q2 2024 net product revenues, with TARPEYO sales reaching $46.3 million (SEK 493.4 million), a 90% year-over-year increase, and Nefecon franchise sales around $53 million.
Operational profitability was reached, excluding one-time costs related to the Asahi Kasei offer and incentive provisions.
Positive clinical milestones: phase III NefIgArd study concluded, phase II proof-of-concept in head and neck cancer and primary biliary cholangitis showed significant results, and phase IIb PBC trial met primary endpoints.
Asahi Kasei announced a public cash offer to acquire all shares at SEK 208 per share, an 83% premium, with board recommendation and major shareholder support; acceptance period runs through August 30, 2024.
Full approval of Kinpeygo in Europe and commercial launch of Nefecon in China marked key milestones.
Financial highlights
Q2 2024 net revenues were SEK 559.8 million, up from SEK 269.4 million year-over-year; TARPEYO net product sales were SEK 493.4 million ($46.3 million), a 90% increase from Q2 2023.
Adjusted operating profit was SEK 70.2 million, but reported operating loss was SEK 31.5 million due to SEK 101.7 million in one-time costs.
Cash position at June 30, 2024 was SEK 797.3 million, with cash burn of SEK 7 million in Q2.
Gross profit for Q2 2024 was SEK 506.3 million, and operating expenses were SEK 537.8 million.
Cash flow used in operating activities for Q2 2024 was SEK 7.0 million, a significant improvement from SEK 163 million in Q2 2023.
Outlook and guidance
Full-year 2024 revenue guidance for the Nefecon franchise raised to $165 million–$185 million, up from previous guidance.
Expectation of continued operating profitability for the remainder of the year, excluding deal-related costs.
Anticipate further revenue growth from TARPEYO and Nefecon, supported by expanded market access, full approvals, and upcoming KDIGO guideline updates.
EUR 10 million milestone payment expected in Q3 from Kinpeygo's full approval in Europe.
Quantify market access friction reduction impact
What is the strategic plan for setanaxib?
How will deal-related costs impact future profitability?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebSCW
Record backlog and 89% y/y revenue growth highlight strong momentum in space projects. - 6 FebNVDA
AI-driven virtual twins and accelerated computing are revolutionizing design and manufacturing. - 6 FebSPKSJF
Record income, strong growth, and robust capital position despite lower interest income. - 6 FebISCTR
Net profit hit TL 67.4 billion in 2025, with strong NIM, fee growth, and solid 2026 outlook. - 6 FebSCW73% revenue growth and record backlog driven by new space contracts and strategic investments.
- 6 FebCDP
2025 FFO/share rose 5.8% with strong leasing and retention; 2026 guidance signals further growth. - 6 FebSCWRevenue at 15.86 mln PLN, backlog 17.14 mln PLN, and major space contracts drive 2025 outlook.
- 6 FebPENG
All proposals passed, with no questions raised during the Q&A session. - 6 FebSCWQ2 2024 revenue up 115% y/y, backlog nearly doubled, Space segment leads growth.
- 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and strong acquisitions.
Calliditas Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Calliditas Therapeutics AB, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. Its lead product candidate is Nefecon that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy. Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage